Contact
Programs
Department
Eugenio Cersosimo, M.D.
Associate Professor of Medicine/ Director of Clinical Research, Texas Diabetes Institute
Eugenio Cersosimo, MD, PhD is currently the medical director of clinical research at the Texas Diabetes Institute and an associate professor of medicine at the University of Texas Health Science Center in San Antonio, Texas. He is board certified in endocrinology, diabetes and metabolism and maintains an active practice in the adult outpatient clinic in San Antonio. Dr. Cersosimo graduated from medical school at the Universidade Federal Fluminense in Rio de Janeiro, Brazil in 1975 and obtained a doctorate degree in physiology at Vanderbilt University in Nashville, Tennessee in 1986.
He completed his training in internal medicine and endocrinology, diabetes & metabolism in the Clinician Investigator Tract at the Mayo Clinic, Rochester, Minnesota in 1994. He started his academic career as an assistant professor of medicine at the State University of New York at Stony Brook, NY and in 2001 transferred to his current position at the University of Texas Health Science Center in San Antonio.
Dr. Cersosimo has authored more than 60 original manuscripts and has received numerous research grants and awards from the National Institutes of Health, Juvenile Diabetes Foundation, American Diabetes Association, Kronkosky Foundation, Howard Hughes Institute, and from various pharmaceutical companies. Presently, he is directly involved in and supervises more than 20 different research projects in areas of his greatest interest: glucose regulation, the entero-pancreatic axis, and insulin therapy & insulin resistance with a focus on cardiovascular and renal complications.
Publications
Abstract |
| Cersosimo E, Xu X, Upala S, Triplitt C, Musi N. Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation: PubMed; 2014 Aug. (Physiol Rep; vol. 2, no. 8). |
Review Article |
| Cersosimo E. Novel Agents for the Treatment of Type 2 Diabetes Diabetes Spectrum 2015 May;27(2):100-112. |
| Eugenio Cersosimo, Carolina Solis-Herrera, Michael E. Trautmann, Jaret Malloy, Curtis L. Triplitt. Assessment of Pancreatic Beta-Cell Function: Review of Methods and Clinical Applications Current Diabetes Review, 2014 Dec;10(1). |
| Cersosimo E. Renal glucose handling and the kidney as a target for anti-diabetic medication Current Trends in Endocrinology 2014 Mar;7:81-94. |
Grants
Scroll table right to view more
Federal |
|
| Funding Agency | NIH |
| Title | Durability of Initial Triple Therapy in Diabetes |
| Status | Active |
| Period | 1/2009 - 8/2018 |
| Role | Co-Investigator |
| Grant Detail | Extended for additional 3 years with anticipated date of completion on December 2017
Funding provided at the same level described for previous 5 years UTHSCSA, American Diabetes Association and Astra-Seneca Combined funding |
| Funding Agency | NIDDK |
| Title | Gradual Diabetes Treatment (GRADE) |
| Status | Active |
| Period | 6/2012 - 6/2018 |
| Role | Consultant |
| Grant Detail | NIH-sponsored prospective clinical trial looking for best combination agents in treatment of diabetes.
Principal Investigator: Ralph DeFronzo,MD |
Private |
|
| Funding Agency | Janssen Pharmaceuticals |
| Title | Effect of Combined Incretin-Based Therapy Plus Canagliflozin On Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients |
| Status | Active |
| Period | 10/2015 - 9/2018 |
| Role | Principal Investigator |
| Grant Detail | Clinical evaluation of the combined effects of canagliflozin and liraglutide in the management of obese type 2 diabetes
PRINCIPAL INVESTIGATOR: EUGENIO CERSOSIMO, MD, PhD |
| Funding Agency | AstraZeneca Pharmaceutical |
| Title | AstraZeneca Dapa-Saxa Study |
| Status | Active |
| Period | 10/2015 - 9/2018 |
| Role | Principal Investigator |
| Grant Detail | Clinical evaluation of the combination therapy of saxagliptin and dapagliflozin in uncontrolled diabetes
PRINCIPAL INVESTIGATOR: EUGENIO CERSOSIMO, MD, PhD Sponsored by Astra-Zeneca Pharmaceutical |
| Funding Agency | American Diabetes Association |
| Title | Preservation of beta-cell function in Pre-Diabetes |
| Status | Active |
| Period | 1/2014 - 6/2017 |
| Role | Co-Investigator |
| Grant Detail | Study examines potential agents capable of slowing progressive beta-cell deterioration in pre-diabetes individuals
Principal Investigator - Ralph DeFronzo, MD |
| Funding Agency | VeroScience |
| Title | Effect of Cycloset on glycemic control in type 2 diabetic patients inadequately controlled on GLP-1 analogue |
| Status | Active |
| Period | 6/2014 - 6/2017 |
| Role | Co-Principal Investigator |
| Grant Detail | Randomized controlled trial to assess improvements in glucose control and in specific vascular surrogate markers using dynamic tests in uncontrolled type 2 diabetes ;patients receiving GLP-1 receptor analogue |
Education
Scroll table right to view more
| Year | Degree | Discipline | Institution |
| 1994 | Clinical Fellowship | Endocrinology (awarded a R29 grant by National Institutes of Health) | Mayo Graduate School Rochester , MN |
| 1991 | Residency | Medicine (NA) | Mayo Graduate School Rochester , MN |
| 1987 | Postdoctoral Fellowship | Surgery and Endocrinology (NA) | Sloan Kettering Memorial New York , NV |
| 1985 | PhD | Physiology (NA) | Vanderbilt University Nashville , TN |
| 1975 | MD | Clinical Sciences (NA) | Universidade Federal Fluminense Rio de Janeiro, Brazil , Brazil |